Aptose Biosciences Inc. agreed to sell up to $20 million of its common shares to Aspire Capital Fund LLC.
Aspire Capital Fund, which invests in a broad range of industries with emphasis in healthcare and technology sector, will buy the shares at Aptose's request until April 7, 2020, subject to certain conditions.
Shares sold under the purchase agreement will be limited to 19.99% of Aptose's outstanding common stock.
Mississauga, Ontario-based Aptose develops personalized cancer therapies in Canada.
